Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Pariser

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
The Journal of Clinical and Aesthetic Dermatology|July 24, 2015
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical TrialsDavid Wirta, David M Pariser, Steven G Yoelin, et al.
Pediatric Dermatology|June 11, 2015
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary HyperhidrosisDee Anna Glaser, David M Pariser, Adelaide A Hebert, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Onychomycosis: Does Cure Equate to Treatment Success?Boni E Elewski, Aditya K Gupta, Ted Rosen, et al.
American Journal of Clinical Dermatology|September 5, 2020
The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne VulgarisStephen K Tyring, Leon Kircik, David M Pariser, et al.
Journal of the American Academy of Dermatology|February 13, 2003
Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trialDavid M Pariser, Nicholas J Lowe, Daniel M Stewart, et al.
Journal of Drugs in Dermatology : JDD|June 20, 2017
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or ChestC William Hanke, Brian Berman, Neil Swanson, et al.
Pediatric Dermatology|November 20, 2018
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trialsAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
Journal of the American Academy of Dermatology|September 19, 2018
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasisMark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
The Journal of Clinical and Aesthetic Dermatology|July 24, 2015
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical TrialsDavid Wirta, David M Pariser, Steven G Yoelin, et al.
Pediatric Dermatology|June 11, 2015
A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary HyperhidrosisDee Anna Glaser, David M Pariser, Adelaide A Hebert, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Onychomycosis: Does Cure Equate to Treatment Success?Boni E Elewski, Aditya K Gupta, Ted Rosen, et al.
American Journal of Clinical Dermatology|September 5, 2020
The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne VulgarisStephen K Tyring, Leon Kircik, David M Pariser, et al.
Journal of the American Academy of Dermatology|February 13, 2003
Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trialDavid M Pariser, Nicholas J Lowe, Daniel M Stewart, et al.
Journal of Drugs in Dermatology : JDD|June 20, 2017
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or ChestC William Hanke, Brian Berman, Neil Swanson, et al.
Pediatric Dermatology|November 20, 2018
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trialsAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
Journal of the American Academy of Dermatology|September 19, 2018
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasisMark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, et al.
Pageof 12